Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Brief: AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile

BRIEF-AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile

- AbCellera Biologics Inc. ABCL.O:

  • ABCELLERA ANNOUNCES POSITIVE TOP-LINE PHASE 2 CLINICAL TRIAL RESULTS FOR ABCL635, DEMONSTRATING SIGNIFICANT REDUCTION IN FREQUENCY AND SEVERITY OF VASOMOTOR SYMPTOMS AND A FAVORABLE TOLERABILITY PROFILE

  • ABCELLERA BIOLOGICS - PHASE 2 RESULTS SHOW BEST-IN-CLASS REDUCTIONS IN VASOMOTOR SYMPTOMS AFTER SINGLE DOSE

  • ABCELLERA BIOLOGICS - ABCL635 SIGNIFICANTLY IMPROVES SLEEP AND PATIENT GLOBAL IMPRESSION OF CHANGE

  • ABCELLERA BIOLOGICS - ABCL635 DEMONSTRATES FAVORABLE TOLERABILITY PROFILE

  • ABCELLERA BIOLOGICS - STUDY MEETS PRIMARY EFFICACY ENDPOINTS WITH SIGNIFICANT REDUCTIONS AT WEEK 4

  • ABCELLERA BIOLOGICS - ABCL635 WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS

Source text: ID:nBwbWgTQra

Further company coverage: ABCL.O


((Reuters.Briefs@thomsonreuters.com;))

Recent news on AbCellera Biologics

See all news